Time filter

Source Type

Matsubara J.,Gastrointestinal Oncology Division | Matsubara J.,Kyoto University | Shimada Y.,Gastrointestinal Oncology Division | Kato K.,Gastrointestinal Oncology Division | And 11 more authors.
Oncology | Year: 2011

Objective: We evaluated the efficacy and safety of bolus 5-fluorouracil (5-FU) and leucovorin combined with weekly paclitaxel (FLTAX) in advanced gastric cancer (GC) patients. Methods: Patients with untreated stage IV GC received paclitaxel 80 mg/m 2 as a 1-hour infusion, followed by 5-FU 600 mg/m 2 as a bolus infusion and L-leucovorin 250 mg/m 2 as a 2-hour infusion on days 1, 8 and 15. Treatment cycles were repeated every 28 days. The primary endpoint was response rate. Results: Thirty-five patients were enrolled. The median age was 62 years (range 34-75). Twenty-one patients (60%) had diffuse-type cancer and 11 had peritoneal metastasis. The confirmed response rate was 43% (95% CI 26-61) with 15 partial responses. Stable disease was observed in 16 (46%) patients. Median progression-free survival and overall survival were 6.8 months (95% CI 5.8-7.4) and 16.2 months (95% CI 10.0-22.8), respectively. Grade 3-4 adverse events were: neutropenia (54%), febrile neutropenia (3%), diarrhea (6%) and sensory neuropathy (11%). Conclusion: FLTAX showed a desirable safety profile, and the efficacy against advanced GC was encouraging. FLTAX may be a good option for GC patients with deteriorated general condition, and a randomized clinical trial in such patients is currently underway. Copyright © 2011 S. Karger AG, Basel.

Loading Gastrointestinal Oncology Division collaborators
Loading Gastrointestinal Oncology Division collaborators